Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology
Executive Summary
The competitive bidding process for Medivation shows just how much big pharma is willing to pay for commercial-stage oncology assets. Now that Pfizer has won the biotech, it will have to prove Xtandi is worth the price.